Highlights

  • Paradigm Biopharmaceuticals Ltd (ASX:PAR) will hold an investor lunch briefing in Melbourne on Wednesday, 23 September 2026.
  • Senior management will present a company update, including progress on the Phase 3 clinical program for Zilosul® (injectable pentosan polysulfate sodium) in knee osteoarthritis.
  • The event will run from 12:00pm to 2:00pm at The Observatory, Garden State Hotel, 101 Flinders Lane, Melbourne, with places strictly limited and existing shareholders given priority.
  • Investors must RSVP by 5:00pm AEST on Friday, 11 September 2026, to Simon White, director of investor relations.

Paradigm Biopharmaceuticals Ltd (ASX:PAR), a late-stage Drug Development company focused on developing therapies for unmet medical needs, has announced details of an investor lunch briefing to be held in Melbourne on Wednesday, 23 September 2026.

The event will provide shareholders and prospective investors with an opportunity to hear directly from the company's senior management team about its development programs and broader corporate activities.

As part of the session, management will provide a company presentation and update on the development of Zilosul® (injectable pentosan polysulfate sodium) for knee osteoarthritis. The presentation is expected to cover progress across Paradigm's Phase 3 clinical program, alongside broader corporate and commercial activities.

Event details and format

The investor briefing will run from 12:00pm to 2:00pm at The Observatory, located within the Garden State Hotel at 101 Flinders Lane, Melbourne VIC 3000.

The company has advised that dress is Business or smart casual. In addition to the formal presentation, attendees will have an opportunity to engage directly with senior management and ask questions during the lunch.

The in-person format gives investors an opportunity for more direct interaction with the company than a conventional webcast or written market announcement.

RSVP process and priority for shareholders

Places at the briefing are strictly limited, with existing Paradigm shareholders receiving priority in the allocation of available places.

Investors wishing to attend must RSVP by 5:00pm AEST on Friday, 11 September 2026, to Simon White, director of investor relations. The RSVP should include the investor's name, confirmation of Shareholder status and any dietary requirements.

Attendance will be confirmed by return email following receipt of the RSVP.

About Zilosul and Paradigm's clinical focus

Paradigm Biopharmaceuticals is a late-stage drug development company focused on discovering, developing and delivering pharmaceutical therapies designed to improve patients' health and quality of life.

The company's current focus includes injectable subcutaneous pentosan polysulfate sodium (iPPS), branded as Zilosul®, for diseases in which inflammation plays a major role.

Knee osteoarthritis is a key focus for the program and is currently in Phase 3 clinical development. Paradigm is investigating the potential of Zilosul in addressing the inflammatory mechanisms associated with the disease.

Conclusion

Paradigm Biopharmaceuticals' Melbourne investor lunch briefing will give shareholders and prospective investors a direct opportunity to hear about progress in the company's Phase 3 program for Zilosul® in knee osteoarthritis, as well as broader corporate and commercial developments.

With places limited and existing shareholders receiving priority, investors interested in attending should submit their RSVP before the 11 September 2026 deadline.

As with any clinical-stage biopharmaceutical program, the ultimate commercial potential of Zilosul® will depend on the outcomes of ongoing Clinical Trials and subsequent regulatory processes.